ISCT, International Society for Cell & Gene Therapy

Announcing our inaugural Keynote Speaker for ISCT 2025 For the first time, ISCT will close out its Scientific Programming with a Keynote Address. Join us on the evening of Friday, May 9th, as Dr. Fred Applebaum discusses the status of our sector and projects into its future. In the late 1970s, Dr. Applebaum led a research team that pioneered the use of autologous bone marrow transplantation, an approach that over the past thirty years has become a practical and accessible means of targeting several types of blood-based cancers. He continues his work today in the treatment of blood cancers, as well as immune-based cancer treatments. He holds a leadership role at the Fred Hutch Cancer Center, where he contributes to setting the vision and standards for clinical research. Dr. Applebaum will close out the ISCT 2025 Scientific Program, speaking on the growth of our field and sharing his perspective into research developments that will impact the sector, contributing to the ISCT 2025 theme of Driving Global Innovation Towards Patient Access. Learn more at ISCT2025.com #ISCT2025

Announcing the current slate of ISCT 2025 Global Showcase Presentations! Leading CGT companies have already secured their spot in the ISCT Global Showcase Theatre to unveil groundbreaking innovations, corporate advancements, and solutions shaping the future of cell and gene therapy. Presenters will tackle key manufacturing challenges, showcase solution-driven offerings, and outline strategies to accelerate patient access. This could be you! Secure your spot now: https://buff.ly/3XRVWpQ

2 weeks left - Register by March 1st! Looking to expand your expertise in cell therapy biomanufacturing? The next ISCT-CMaT course on Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory course starts February 24! 🔹 Designed and led by global Subject Matter Experts from academia, industry, and regulatory sectors 🔹 Flexible learning with self-paced modules + live virtual Q&A sessions 🔹 Live Q&As are scheduled in the morning Asia time, making it ideal for learners in Asia while still accessible for North America 🔹 Join 350+ graduates who have gained critical skills in cell biomanufacturing processes and regulatory standards 🔹 ANAB-accredited to ensure an industry-recognized skillset Don’t miss out on this opportunity to advance your career! 𝘚𝘱𝘦𝘤𝘪𝘢𝘭 𝘳𝘢𝘵𝘦𝘴 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘮𝘦𝘮𝘣𝘦𝘳𝘴, 𝘦𝘮𝘦𝘳𝘨𝘪𝘯𝘨 𝘦𝘤𝘰𝘯𝘰𝘮𝘪𝘦𝘴, 𝘢𝘯𝘥 𝘴𝘵𝘶𝘥𝘦𝘯𝘵𝘴 Register now: 🔗 https://buff.ly/48odEmK

Why attend the ISCT 2025 Roundtable Program? Here's what co-chair Qasim Rafiq, MEng, PhD, UCL has to say. View full program at: https://buff.ly/3EnAAcy In interactive roundtable sessions, delegates collaborate to drive real actionable solutions to the most pressing real-world challenges they encounter daily. By working closely with over 40 ISCT standing committees, the Roundtable Committee ensures that sessions reflect the practical needs and experiences of professionals from across the CGT spectrum Special thanks to the organizers for each of the following sessions. Stay tuned for more! What Really Are Mesenchymal Stromal Cells? • Manoj Lalu, The Ottawa Hospital Decentralized Manufacturing - New Technologies and Strategies • Dominic Clarke, Cryoport Systems • Steve Oh • Dalip Sethi, PhD, MBA, Terumo Blood and Cell Technologies Capital Markets 101 - Demystifying Fundraising and Investment Strategies for Your Startup • Phil Vanek, Gamma Biosciences • Asthika Goonewardene, Truist Securities Cheaper CAR Ts - Are They as Good? • Bill Milligan, Steminent Biotherapeutics Is Germline Editing Feasible and Should it be Permissible? • Miguel Forte, Kiji Therapeutics • Bruce Levine, University of Pennsylvania Learning from Clinical Trial Failures - The Case of Viral Specific Cytotoxic T Lymphocytes • Anna Kopitna, Mendus AB • Jaap Jan Boelens, MD PhD, Memorial Sloan Kettering Cancer Center (Global Regulatory Perspectives) Donors - The Allogeneic Problem • Scott Burger, MD, Advanced Cell and Gene Therapy • Janet Macpherson, PhD, NSW Health • Bambi Grilley, RPh, CIP, CCRC, CCRP, RAC, Baylor College of Medicine • Christopher Bravery, PhD, Advbiols • Dominic Wall, PhD, FFSc (RCPA), Peter MacCallum Cancer Centre • Gabrielle O'Sullivan, PhD, MPH, NSW Health • Kevin Bosse, Ph.D., RAC-US, CABP(H), Nationwide Children's Hospital • Srinivasan Kellathur N, PhD, Roche Are They Really Worth It? Understand Risks for Patients Receiving Genetically-Modified Immune Effector Cells • David Steffin, MD, Baylor College of Medicine • Nirali Shah, MD, National Cancer Institute (NCI) The Global Approval Pathway - Realistic Solution or Distant Utopia? • Mo Heidaran, PhD, Cellx Inc. Consulting Safety versus Scalability - The Allogeneic iPSC Problem • Julie G. Allickson, PhD, Mayo Clinic • Uma Lakshmipathy, PhD, Thermo Fisher Scientific • Natalie Francis, PhD, MBA, King’s College London

Are you part of a startup company in Cell & Gene Therapy? Apply by Feb 14 to the ISCT Innovation Zone for a chance to win $300,000 USD in services. Limited space remains! The inaugural ISCT Innovation Zone Award is an exclusive opportunity for disruptive start-ups participating in the 2025 ISCT Innovation Zone program who are developing a therapeutic product. The recipient will be chosen by ISCT, in collaboration with industry leaders and expert judges, based on the impact of their product and their presentation at ISCT 2025 in New Orleans. Details: https://buff.ly/3XTHtIB

Late Breaking Abstract Submissions Opening March 3! This is your chance to share novel data with one of the most sought-after audiences in our sector. Reach 3000+ international delegates at ISCT 2025 New Orleans. Submissions will only be open for one week - 𝗠𝗮𝗿𝗰𝗵 𝟯-𝟭𝟬 - make sure your data and approvals are ready to go! Save to your calendar: https://buff.ly/4jRocBZ #ISCT2025

Looking to expand your expertise in cell therapy biomanufacturing? The next ISCT-CMaT course on Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory course starts February 24! 🔹 Designed and led by global Subject Matter Experts from academia, industry, and regulatory sectors 🔹 Flexible learning with self-paced modules + live virtual Q&A sessions 🔹 Live Q&As are scheduled in the morning Asia time, making it ideal for learners in Asia while still accessible for North America 🔹 Join 350+ graduates who have gained critical skills in cell biomanufacturing processes and regulatory standards 🔹 ANAB-accredited to ensure an industry-recognized skillset Don’t miss out on this opportunity to advance your career! 𝘚𝘱𝘦𝘤𝘪𝘢𝘭 𝘳𝘢𝘵𝘦𝘴 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘮𝘦𝘮𝘣𝘦𝘳𝘴, 𝘦𝘮𝘦𝘳𝘨𝘪𝘯𝘨 𝘦𝘤𝘰𝘯𝘰𝘮𝘪𝘦𝘴, 𝘢𝘯𝘥 𝘴𝘵𝘶𝘥𝘦𝘯𝘵𝘴 Register now: 🔗 https://buff.ly/48odEmK

Don't miss out - seats are in-demand for this full-day workshop on Immune Monitoring & Immunobiology. Taking place on the pre-conference day for ISCT 2025 New Orleans, this course is an enriched opportunity to learn about strategies for standardizing and leveraging immune monitoring towards patient outcomes and treatment implementation. Learn more: https://buff.ly/414htxd Special thanks to our sponsors at Sobi - Swedish Orphan Biovitrum AB (publ), and our planning faculty: Jaap Jan Boelens, MD PhD Patrick Hanley, Ph.D. Elani Fourie Wiest, PhD

The full ISCT 2025 Roundtable Program is now available! View at https://buff.ly/3EnAAcy The ISCT Roundtable Program is one of the most anticipated flagship ISCT events. In these interactive roundtable sessions, delegates collaborate to drive real actionable solutions to the most pressing real-world challenges they encounter daily. By working closely with over 40 ISCT standing committees, the Roundtable Committee ensures that sessions reflect the practical needs and experiences of professionals from across the CGT spectrum We'd like to shout out the committee that has been working hard to make this possible: Dominique FARGE, MD, PhD Qasim Rafiq, MENG, PhD Lizette Caballero, BSc, MLS(ASCP)CM Wade Atkins, MS, MLS(ASCP)SBB, CABP(H)(AABB), CQA(ASQ) Emily Blyth, B.Med (Hons), FRACP, FRCPA, PhD Kevin Bosse, Ph.D., RAC-US, CABP(H) Dominic Clarke, PhD Kunihiko Suzuki, MBA Jonathan Yeh, MBA, PhD

Unpublished, unpresented data at ISCT 2025 You asked - we listened! Leading into ISCT 2025 New Orleans, we're spotlighting presentations with novel data. Be the first to see groundbreaking updates from key opinion leaders who drive CGT translation across the globe. Learn about early research on replicating retrovirus (RRV) in in vivo gene therapy with Geoffrey Stephens, Ph.D., AiCella in "Advanced Analytics: Harnessing AI and Cutting-Edge Technologies to Accelerate Cell Therapy Development," chaired by Marinna Madrid, PhD, Cellino Session topics and speakers online now: https://buff.ly/3DjduTU Register now: https://buff.ly/429LjRN #ISCT2025